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Electroconvulsive therapy can be eﬀective in severe or treatment resistant neuroleptic malignant syndrome patients. Anesthesia
and use of muscle relaxant agents for electroconvulsive therapy in such patients may encounter anesthesiologists with speciﬁc
challenges. This case report describes successful management of anesthesia in 28-year-old male patient undergoing eight
electroconvulsive therapy sessions for treatment of neuroleptic malignant syndrome.
1.Introduction
Neuroleptic malignant syndrome (NMS) is a rare, unpre-
dictable, and potentially fatal complication of certain anti-
psychotic medications. The incidence and mortality rates
of NMS are approximately 0.07% to 2.2%, and 15%–25%,
respectively [1]. Typical characteristics consist of hyperther-
mia, altered level of conscious, muscle rigidity, catatonia,
autonomic dysfunction, and elevation of Creatine Kinase
(CK) level. All the previous ﬁndings are not necessary
for diagnosis [1]. Bromocriptine, dantrolene, and benzodi-
azepines are eﬀective in the treatment of NMS [2, 3]. Some
authors recommend that electroconvulsive therapy (ECT)
may be eﬀective if signs and symptoms are resistant to
supportive care and pharmacotherapy [4, 5].
There are a known sameness between the clinical symp-
toms of NMS and malignant hyperthermia (MH) [6]; there-
fore several reports have incited some controversy regarding
the safety of the use of known triggering agents of MH
such as succinylcholine in patients with a history of NMS
[6–8]. Anesthesia and muscle relaxation for ECT in such
patients poses speciﬁc challenges to anesthesiologists. This
case report describes successful use of propofol-remifentanil
without muscle relaxant in a patient undergoing ECT for the
treatment of NMS.
2.CaseReport
A 28-year-old male with a history of bipolar mood disorder
and moderate mental retardation was admitted to hos-
pital with increasing body temperature, muscle rigidity,
diaphoresis, cognitive impairment, and some degrees of
impaired consciousness. He had been taking thioridazine
a n dv a l p r o a t ef o rap e r i o do f6m o n t h sp r i o rt oh o s p i t a l
admission. On examination the patient was mute and
showedunusualposturescharacteristicofcatatonia.Hisvital
signs were as follows: temperature (38.2◦C), blood pressure
131/82mmHg, heart rate 114beats/min, and respiratory
rate 18. The CK level was markedly elevated (1245U/L)
other laboratory results, including electrolytes, were slightly
elevated. He had several psychiatric hospitalizations, during
the last years prior to the present episode, and lived
in a chronic mental disorder institute. In family history
his monozygotic twin had died with NMS manifestations
about one year ago. Antipsychotic drugs were stopped, and
diagnosis of NMS was made, because the patient met three2 Case Reports in Medicine
major (rigidity, hyperthermia, rising of CK) and three minor
criteria (tachycardia, diaphoresis, cognitive impairment) of
NMS. After six days because of progressive catatonia and
muscular rigidity ECT under anesthesia was considered.
After preoxygenation with 100% O2 via face mask,
anesthesia was induced with remifentanil 1.5µg/kg and
propofol 1.5mg/kg IV slowly. Then the ECT stimulus was
applied, and it produced an ensuing seizure. Succinylcholine
and any other muscle relaxants were avoided. The doses of
propofolandremifentanilremainedﬁxedinalleightsessions
of ECT and there was no need for adding other anesthetic
or analgesic drugs for inducing anesthesia. Bilateral ECT
was administered using an ECT stimulator (brief pulse rate,
analog-output ECT: type RF class 1. ARA 121; ARA Co
Ltd., Tehran, Iran). The ﬁrst selected stimulus intensity was
20% that induced a 32-second relatively tense seizure. The
stimulus intensity titrated based on previous seizure length
and reached 50% in the last session. The range of seizure
duration was 24–37 second (mean 27 second). The mean
time from inducing anesthesia to returning spontaneous
ventilation was 8 minutes [7–10], and patient opened his
eyes by commend after 9–14 minutes (mean 11 minutes).
The body temperature was measured on several occasions
following ECT, at intervals of 3-4hour. We did not observe
any changes in body temperature. After eight ECT sessions
that was done three times a week, the psychotic symptoms
improved considerably, CK level turned back toward normal
ranges slightly, and the patient was discharged from hospital
without further complications.
3. Discussion
Although NMS and MH result from diﬀerent pathophysio-
logicalmechanisms[1,9],however,theyhavesomecommon
clinical features. So patients susceptible to NMS may be
vulnerable to developing MH. ECT has been used as a treat-
ment for NMS, because it supposedly increases circulating
catecholamines, including dopamine, in the central nervous
system [2, 3].
Succinylcholine remains the most commonly used mus-
cle relaxant to decrease the strong muscle contractions
associated with ECT-induced seizure activity [10]. However,
the use of this rapid and short-acting drug can accompany
with side eﬀects in patients with history of susceptibility
to MH, NMS, and catatonic schizophrenia [11, 12]. And it
has been suggested that the use of succinylcholine should be
avoided in patients with a history of these diseases [13].
Although nondepolarizing agents has been used success-
fully in the treatment of NMS, some authors suggest that
these drugs are associated with increases in temperature,
CK levels, and leukocytosis [14] too, so it may be advisable
to avoid administering depolarizing and nondepolarizing
muscle relaxants to patients with NMS. Based on this
information,wedecidedtoperformECTusingremifentanil-
propofol without muscle relaxant in this case. In the sole
related case report that we ﬁnd, Franks et al. [15]p e r f o r m e d
ECT on an MH susceptible patient using thiamylal without
anymusclerelaxant,butthepatientrequiredphysicalcontrol
during the seizure and experienced severe muscle pain after
the procedure.
Remifentanil is an ultra-short-acting opioid with a rapid
onset and an ultrashort context sensitive half-time [16].
Propofol has signiﬁcant myorelaxant properties on pharyn-
geal and laryngeal structures, so it is the agent of choice
for intubation without muscle relaxant [17]. On the other
hand, there are some reports that the infusion of propofol
and remifentanil slightly decrease both the train-of four
ratio in comparison with the preoperative value [18]a n d
succinylcholine-induced fasciculation [19, 20]. Based on the
results reported herein, and the aforementioned pharmaco-
logicalproperties,individualswithNMSmaybeatproviding
general anesthesia using remifentanil-propofol boluses with-
out neuromuscular blocking agents and were able to com-
plete sessions of ECT without any associated complications.
4. Conclusion
Itislikelythatcombinationofremifentanil-propofolwithout
muscle relaxants for ECT in NMS patients is safe and eﬀec-
tive.
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